AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Epimmune and Genencor Achieve Preclinical Milestone.(Brief Article)
2002 FEB 6 - (NewsRx.com & NewsRx.net) -- Genencor International, Inc., and Epimmune, Inc., have identified an EpiGene clinical product candidate for the lead program in their collaboration, a therapeutic hepatitis B vaccine. Epimmune received an undisclosed milestone payment from Genencor as a result of the selection of the product candidate.
In July 2001 Genencor exclusively licensed Epimmune's epitope and PADRE technologies and related intellectual property rights on a worldwide basis for vaccines to treat or prevent hepatitis C (HCV), hepatitis B (HBV) and human papilloma virus (HPV), and the two companies entered into a 30-month collaboration focused on development of therapeutic vaccines for the three viral indications. At that same time, Genencor took an initial 10% equity stake in Epimmune. In December 2001, Genencor invested again in Epimmune's private equity ...
- Genencor and Epimmune Form Therapeutic Vaccine Collaboration For Three...
- Press release article from: PR Newswire July 10, 2001 700+ words
...therapeutic vaccine platform at Genencor." Epimmune brings epitope discovery...The collaboration provides Genencor access to Epimmune's extensive proprietary...chief executive officer of Epimmune. "Genencor is a premier biotechnology...
- GENENCOR AND EPIMMUNE FORM THERAPEUTIC VACCINE COLLABORATION FOR THREE...
- Press release article from: PR Newswire July 10, 2001 700+ words
...therapeutic vaccine platform at Genencor." Epimmune brings epitope discovery...The collaboration provides Genencor access to Epimmune's extensive proprietary...chief executive officer of Epimmune. "Genencor is a premier biotechnology...
- Epimmune and Genencor Announce the Achievement of Pre-Clinical Milestone From...
- Press release article from: PR Newswire January 15, 2002 700+ words
...candidate. In July 2001 Genencor exclusively licensed Epimmune's epitope and PADRE...relationship between Genencor and Epimmune and underscores the commitment...visit http://www.epimmune.com/ . About Genencor Genencor International...
- Epimmune and Genencor Announce The Achievement of Pre-Clinical Milestone From...
- Press release article from: PR Newswire January 15, 2002 700+ words
...candidate. In July 2001 Genencor exclusively licensed Epimmune's epitope and PADRE...relationship between Genencor and Epimmune and underscores the commitment...visit http://www.epimmune.com/. About Genencor Genencor International...
- Epimmune and Genencor Extend Collaboration for Therapeutic Vaccines For Three...
- Press release article from: PR Newswire October 21, 2002 700+ words
...today announced that Epimmune and Genencor International, Inc...the collaboration, Genencor fully funds Epimmune's research and development...collaboration. In addition, Genencor will make milestone payments to Epimmune upon successful completion...
- Epimmune and Genencor Achieve Preclinical Milestone.
- Newspaper article from: Hepatitis Weekly February 4, 2002 700+ words
...NewsRx.net) -- Genencor International, Inc., and Epimmune, Inc., have identified...candidate. In July 2001 Genencor exclusively licensed Epimmune's epitope and PADRE...relationship between Genencor and Epimmune and underscores the...
- Epimmune to Work With Firm on Disease Treatments.(Genencor International...
- Magazine article from: San Diego Business Journal WEBB, MARION July 16, 2001 700+ words
...biotechnology firm Genencor International Inc...percent stake in Epimmune, or 1.2 million...said. By 2003, Epimmune and Genencor hope to enter clinical...the agreement, Genencor retains worldwide...approved products. Epimmune will receive royalties...
- Epimmune and Genencor Announce HBV Vaccine Candidate.
- Newspaper article from: Hepatitis Weekly January 28, 2002 700+ words
...product candidate. In July 2001 Genencor exclusively licensed Epimmune's epitope and PADRE technologies...an initial 10% equity stake in Epimmune. In December 2001, Genencor invested again in Epimmune's private equity financing to...